Cargando…
Therapy of murine tumors with p53 wild-type and mutant sequence peptide- based vaccines
The BALB/c Meth A sarcoma carries a p53 missense mutation at codon 234, which occurs in a peptide, termed 234CM, capable of being presented to cytotoxic T lymphocytes (CTL) by H-2Kd molecules (Noguchi, Y., E.C. Richards, Y.-T. Chen, and L.J. Old. 1994. Proc. Natl. Acad. Sci. USA. 91:3171-3175). Immu...
Formato: | Texto |
---|---|
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
1996
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2192493/ https://www.ncbi.nlm.nih.gov/pubmed/8666894 |
Ejemplares similares
-
Mutant and Wild-Type Tumor Suppressor p53 Induces p300 Autoacetylation
por: Kaypee, Stephanie, et al.
Publicado: (2018) -
Recent findings on the role of wild-type and mutant p53 in cancer development and therapy
por: Babamohamadi, Mehregan, et al.
Publicado: (2022) -
The Competition of Yin and Yang: Exploring the Role of Wild-Type and Mutant p53 in Tumor Progression
por: Cai, Bi-He, et al.
Publicado: (2023) -
Editorial: Advances in wild type and mutant p53 research in cancer
por: Hernández-de la Cruz, Olga N., et al.
Publicado: (2022) -
Loss of wild-type p53 promotes mutant p53-driven metastasis through acquisition of survival and tumor-initiating properties
por: Nakayama, Mizuho, et al.
Publicado: (2020)